Southampton, UK-headquartered company Synairgen has treated the first patient in the UK as part of a global Phase III trial evaluating its inhaled COVID-19 treatment SNG001 in hospitalised patients. SNG001 is an inhaled formulation of interferon beta-1a, a naturally occuring protein which is believed to kickstart the body’s antiviral responses. The trial – called SG018 – is being conducted in around 20 countries and will seek to enrol a total of 610 COVID-19 patients who require supplemental oxygen. Source: Pharmatimes 13/1/21